Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1,3-dihydro-6-methyl-7-hydroxy-3-(4-chlorophenyl)furo(3,4-d)pyridine
2. Bn 1270
3. Bn-1270
4. Cicletanide
5. Cicletanine Hydrochloride
6. Cycletanide
7. Justar
8. Tenstaten
1. Cycletanide
2. 89943-82-8
3. Bn-1270
4. Win 90,000
5. Win-90000
6. Chg7qc509w
7. 3-(4-chlorophenyl)-6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol
8. Tenstaten
9. Justar
10. (+/-)bn-1270
11. Cicletanina
12. Cicletaninum
13. Cicletaninum [latin]
14. (+/-)-cicletanine
15. Cicletanina [spanish]
16. Unii-chg7qc509w
17. Cicletanine [usan:inn:ban]
18. Cicletanine [mi]
19. Cicletanine [inn]
20. Cicletanine (usan/inn)
21. Cicletanine [usan]
22. (+-)-bn-1270
23. Cicletanine [mart.]
24. Schembl49794
25. Cicletanine [who-dd]
26. Chembl191886
27. (r)-(-)-cicletanine
28. Dtxsid70868972
29. Chebi:135078
30. (+-)-3-(p-chlorophenyl)-1,3-dihydro-6-methylfuro(3,4-c)pyridin-7-ol
31. Akos022665941
32. Db12766
33. Bn-50417
34. Bn-50418
35. Ds-017342
36. D03487
37. (+/-)-bn-1270
38. Q5119443
39. 3-(4-chlorophenyl)-6-methyl-1h,3h-furo[3,4-c]pyridin-7-ol
40. Furo(3,4-c)pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (+-)-
Molecular Weight | 261.70 g/mol |
---|---|
Molecular Formula | C14H12ClNO2 |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 1 |
Exact Mass | 261.0556563 g/mol |
Monoisotopic Mass | 261.0556563 g/mol |
Topological Polar Surface Area | 42.4 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 294 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Diuretics
Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)
C - Cardiovascular system
C03 - Diuretics
C03B - Low-ceiling diuretics, excl. thiazides
C03BX - Other low-ceiling diuretics
C03BX03 - Cicletanine
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?